BrainsWay Deep TMS Study Shows 70% Reduction in Suicidal Ideation in Major Depression
Summary
BrainsWay announced the publication of peer-reviewed data in the Journal of Affective Disorders showing significant reductions in suicidal ideation among patients with major depressive disorder treated with Deep Transcranial Magnetic Stimulation. The analysis was a secondary evaluation of BrainsWay's previously published multisite randomized non-inferiority trial, which compared its accelerated SWIFT protocol against standard once-daily Deep TMS and supported the FDA's September 2025 clearance of SWIFT. Deep TMS is FDA-cleared for major depressive disorder but is not specifically cleared for treating or preventing suicidal ideation or behavior.
Why it matters
Suicidal ideation is a devastating symptom of major depression with few fast-acting, non-pharmacological treatment options; growing peer-reviewed evidence that an already-cleared device may help could shift clinical practice ahead of any new dedicated regulatory clearance.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial